drugset / Trial / NCT03100045
Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)
Phase 1
Completed
18 enrolled
Johns Hopkins University
Frantz Viral Therapeutics, LLC · collabUniversity of Wisconsin, Madison · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This open label study investigates a novel non-surgical approach to the treatment of HPV-associated anal intraepithelial neoplasia, using Artesunate suppositories.
Timeline
- Start
- 2017-04-20
- Primary completion
- 2021-10-06
- Completion
- 2021-10-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Artesunate | Small molecule | 200 mg | Other |
| Subject | Artesunate | Small molecule | 400 mg | Other |
| Subject | Artesunate | Small molecule | 600 mg | Other |